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Background: We aim to characterize the heterogeneous circulating tumour cells (CTCs) in peripheral blood,
independently of physical or immunological purification, by using patient-derived xenografts (PDXs) models. CTC
studies from blood generally rely on enrichment or purification. Conversely, we devised a method for the inclusive
study of human cells from blood of PDX models, without pre-selection or enrichment.
Methods: A qRT-PCR assay was developed to detect human and cancer-related transcripts from CTCs in PDXs.
We quantified the EPCAM and keratins CTC markers, in a PDX cohort of breast cancer. The murine beta actin gene
was used for normalization. Spearman’s rho coefficients were calculated for correlation.
Results: We demonstrated, for the first time, that we can quantify the content of CTCs and the expression of human
CTC markers in PDX blood using human-specific qRT-PCR. Our method holds strong potential for the study of CTC
heterogeneity and for the identification of novel CTC markers.
Conclusions: The identification and the relative quantification of the diverse spectrum of CTCs in patients, irrespective
of EPCAM or other currently used markers, will have a great impact on personalized medicine: unrestricted
CTCs characterization will allow the early detection of metastases in cancer patients and the assessment of
personalized therapies.
Keywords: CTCs, RT-qPCR, PDXBackground
Metastases from primary tumours account for the great
majority of cancer-related deaths [1]. This process is
thought to involve a series of sequential steps, including
the release of circulating tumour cells (CTCs) into blood
stream [1, 2]. CTCs have been detected in the peripheral
blood of patients with advanced cancers of different ori-
gin [3]. Recently, liquid biopsy focusing on the analysis
of CTCs has received enormous attention because of its
clinical implications [4–6]. The elucidation of CTC’s role
might represent a turning point in understanding the
evolution of tumours during treatment and progression
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sion, monitoring the effects of systemic therapies, and
stratification of patients [4]. CTC analysis might provide
an alternative route for primary diagnosis of tumours,
and for restaging/molecular analysis of metastatic le-
sions. At present, CTCs are used as biomarkers in > 270
clinical trials registered at ClinicalTrials.gov [5]. In
on-going interventional studies, the clinical utility of
CTC use for therapeutic decisions is being evaluated [7].
To date, however, only incomplete information is avail-
able on CTC molecular and biological heterogeneity, and
significance. The fact that CTCs are extremely rare, even
in patients with advanced metastatic cancers (estimated at
one CTC/ billion normal blood cells), and that they may
be poised on the verge of apoptosis, has made their ana-
lysis contingent upon technological constraints, posing ale is distributed under the terms of the Creative Commons Attribution 4.0
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although the potential CTC applications appear very
promising, there is a critical need for increased detec-
tion sensitivity, requiring appropriate, high throughput,
and reliable platforms for the isolation or rare tumour
cells from blood.
It is thought that only a minor and variable fraction of
CTCs represents viable metastatic precursors or tumour-
initiating cells [11]. Aberrant activation of epithelial-
mesenchymal transition (EMT) in adherent epithelial cells
has been implicated in preclinical models as a prerequisite
for invasive growth and metastatic spread [12–14]. EMT
results in a reduced expression of epithelial markers, in-
creased plasticity and capacity for migration and invasion,
thus enabling detachment of tumour cells from a primary
site and their passage into the circulation [12]. It also re-
duces their competence to initiate overt metastasis [15].
Therefore, the most accepted view is currently that
tumour cells with a partial EMT have the highest plasticity
and represent tumour cells with stem cell-like properties
(i.e. metastatic potential) [4, 16, 17]. The detection of
CTCs with such an intermediate phenotype seems to be
now of the utmost importance, and thus the definition of
a wider range of specific markers is required. In general,
this plastic phenotype is characterized by partial down-
regulation of epithelial markers, and partial up-regulation
of mesenchymal markers [5]. Overall, thus far, there is still
an incomplete knowledge on the heterogeneity of CTCs
[18, 19]; further molecular characterization may give bet-
ter insights, and help to distinguish clinically relevant
CTCs [20]. Most of the current CTC isolation techniques
rely on antibody-based capture. Epithelial markers
expressed by tumours but not on blood cells have been
frequently used to purify cancer cells [6, 21]. The Cell-
Search system (Menarini Silicon Biosystems), is highly
standardized and is currently being evaluated for clinical
applications, with CTCs defined as the subset of EpCAM
(epithelial cell adhesion molecule)-captured cells, that are
confirmed as positive for cytokeratins (KRT8, 18, and 19)
and negative for CD45 [22]. However, this technique suf-
fers from relatively low sensitivity: only a fraction of pa-
tients with metastatic cancer scores positive for CTCs,
with a median yield of approximately one CTC per milli-
litre and typically low purity [23]. Thus, while progress
has been made in the development of microfluidic devices,
the discovery and validation of CTC markers is still in its
infancy. Indeed, studies on CTCs have been hampered by
reliance on a restricted pool of markers [3, 24], often
leading to false-negative results [25]. To address these
technical challenges, methods for the detection of CTCs
from clinical samples should measure both the epithelial
and the mesenchymal-like populations, as well as tumour
cells with stem cell-like properties [16, 26]. In other
words, there is a need for a broad-spectrum enrichmentof CTCs based on cell surface epithelial and mesenchymal
markers [12, 27], to avoid loss of CTCs with high pheno-
typic plasticity.
Here, we describe a novel approach that does not rely
on the use of epithelial markers such as EPCAM for de-
tection of CTCs in patient-derived xenografts (PDXs).
PDXs are generated by transplanting patients’ tumour
cells or tissues, obtained either by surgical resection or bi-
opsy, into immunodeficient mice [28, 29]. The develop-
ment of PDXs has significantly enhanced cancer research:
these models have been established for different types of
cancers, are biologically stable and reflect the patients’ tu-
mours in terms of histology, gene profiles, inflammation,
and therapeutic response. Thus, PDX models found gen-
eral application in preclinical screening and evaluation of
drugs, identification of therapeutic targets and bio-
markers, biological studies, and personalized medicine
strategies [29]. At present, CTCs have also been used to
generate PDX models, with a great potential for studying
tumorigenicity, and for the phenotypic and genetic
characterization of CTCs themselves [29]. In this study,
we took advantage of PDXs to study human CTCs in a
murine genetic background, using human-specific
RT-quantitative PCR (RT-qPCR) on RNA from total blood
mononuclear cells. By using this highly specific and sensi-
tive approach, without any CTC pre-isolation, we could
identify and measure human CTC mRNAs irrespectively
of the EPCAM content. In turn this procedure has the po-
tential to identify membrane proteins, that could repre-
sent molecular handles for the immune-isolation of viable
CTCs. Our approach could represent a major step to-
wards the complete coverage of molecular and cellular
heterogeneity in CTCs.
Methods
Patient-derived xenograft models establishment and
blood samples collection
All PDXs used in the study were established upon approval
of hospitals’ ethical committees, and an informed consent
was signed for each patient. The major clinical characteris-
tics of the PDX models used in this study are reported in
Additional file 1: Table S1. Tumour samples were grafted
in the interscapular region of 6- to 8-week-old female athy-
mic nude mice (Athymic Nude-Foxn1nu, ENVIGO-Harlan
Laboratories, Gannat, France). Growing tumours were
serially transplanted onto recipient mice, underwent com-
parative examination to confirm preservation of their
histological features and were live-frozen to immortalize
the model. Blood was collected from mice with tumours
reaching the ethical size (tumour volume > 1500 mm3) and
eventually sacrificed in compliance with the indications
provided in the protocol, as approved by the animal ethical
committee and by the French Ministry of agriculture food
and forestry. Briefly, at least 600–800 μl of whole blood
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under xylazine-ketamine anaesthesia. Blood samples were
transferred in Eppendorf tubes containing 0.5 M EDTA,
and erythrocytes were lysed at room temperature using the
ACK Lysing Buffer (Lonza Walkersville, Inc., Allendale, NJ,
USA). PBMC (Peripheral Blood Mononuclear Cells) were
frozen in liquid nitrogen and stored at − 80 °C.
RNA isolation and species-specific primers design
For gene expression studies, mouse or PDX PBMC, with
or without human CTCs, were lysed by adding 500 μl of
Trizol (Invitrogen, Carlsbad, CA, USA). RNA quantity and
purity were assessed using a NanoDrop ND-1000 Spectro-
photometer (Thermo Fischer Scientific, Wilmington, DE,
USA). Total RNA (~ 1 μg) was reverse-transcribed in a
final volume of 20 μl using random hexamers and Super-
Script II (Life Technologies, Carlsbad, CA, USA). For each
gene, human-specific primers were designed using
Primer-BLAST at the National Center for Biotechnology
Information and verified using the Genome Browser
UCSC In-Silico PCR tool; primers with sequence homolo-
gies between Homo sapiens and Mus musculus were ex-
cluded. If possible, primers that amplified regions
spanning two or more exons or the 5′- or 3’-UTR regions
of the transcript were selected, to avoid amplification of
genomic sequences and operator or laboratory contamin-
ation (Additional file 2: Table S2). To validate species-
specificity, all oligonucleotides were tested in RT-PCR on
RNA pools from human cell lines (ZR-75-1, MCF-7,
MDA-MB-231 breast cancer, and MDA-MB-435 melan-
oma cells) and Sv/129 mouse blood. One μl of cDNA was
amplified using DreamTaq DNA Polymerase (Life Tech-
nologies), according to the manufacturer’s instructions.
Single nested PCR was performed with 1 μl of a 1:10 di-
luted pre-amplification reaction, by using DreamTaq DNA
Polymerase (Life Technologies). PCR products were then
analyzed on a 2% low melting point agarose gel.
Quantitative PCR
Gene specific primers and conditions used in qPCR are
listed in Additional file 2: Table S2. To ensure detection
of very rare human transcripts, one μl of each cDNA
was subjected to 14-cycles pre-amplification with
DreamTaq DNA Polymerase, and human specific oligo-
nucleotides: for both human reference and target tran-
scripts, pre-amplification was performed with annealing
at 58 °C for 5 min. qPCR was then performed using
nested specific primers and Dual-Lock™ Taq DNA poly-
merase on a CFX96 Touch (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). qPCR was carried out in 10 μl vol-
ume using PowerUp SYBR Green Master Mix (Applied
Biosystems™), and 1 μl of a 1:10 diluted
pre-amplification reaction. Primers were added to a final
concentration of 0.2 μM or 0.3 μM each, depending onthe gene, as detailed in Additional file 2: Table S2. After
the initial step (2 min at 50 °C for polymerase activation
and 2 min of denaturation at 95 °C), 40 cycles were car-
ried out by denaturation at 95 °C for 15 s, and anneal-
ing/extension as indicated in Additional file 2: Table S2.
The melting curves were evaluated, to confirm the speci-
ficity of each reaction. Samples were analyzed in dupli-
cate for mouse Actb reference (mActb), while for each
human transcripts qPCR was repeated in four or five
independent assays. RNAs from naïve mouse blood
(negative control) and human cell lines (positive control)
were included in each PCR assay.
The method based on the expectation–maximization
(EM) algorithm, as implemented in the R ‘nondetects’
package, was applied to estimate missing Ct values [30].
This function returns a qPCRset object with non-detects
replaced by their imputed values. Non-detects in qPCR
data represent data missing not at random, and the EM
algorithm provides a method to obtain maximum likeli-
hood estimates in the presence of missing data by itera-
tively calculating the conditional expectation. This
requires estimating the distribution of gene expression
given a non-detect; the process is repeated until conver-
gence. Lastly, estimates of the missing data will be ob-
tained and used to impute the non-detect values. PDX
samples with at least one replicate for each human refer-
ence, having estimated Ct value larger than 40, were
deemed as CTC-negative and excluded from further
analyses. Estimated Ct values for target genes higher
than 40 were thresholded to 40, and median Ct values
used for each gene. The relative quantities of human ref-
erence genes normalized on the mouse Actb gene were
calculated with the ΔCt method using the R ‘HTqPCR’
package. Conversely, for CTC relative measures, the
quantities of human target genes were normalized on
the quantities of each human reference gene. All statis-
tical analyses, i.e. Spearman’s rho correlation coefficient
calculation, were performed using SPSS (version 23) and
p values were two-sided.
Results
Species-specific PCR for detection of human circulating
tumour cells in PDX blood
Peripheral blood samples were collected from 28 PDXs
and 3 naïve mice (negative controls). Following chemical
erythrocytes depletion, RNA was extracted from the
whole blood cell pellet, reverse-transcribed and tested
for expression of the human EPCAM and KRT19 CTC
markers. Human coding region-specific primers were
also designed for two reference genes, OAZ1 and ACTB,
to avoid detection of mouse homologues and amplifica-
tion of human genomic DNA (Additional file 2: Table
S2). The species-specificity of the protocol was assessed
using naïve mouse blood samples and human cell lines
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mer optimization, cDNA from human cell lines and con-
trol mice was pre-amplified, and further subjected to
single-gene nested PCR (representative assays are re-
ported in Fig. 1). Once verified the species-specificity of
the primers, the cDNA from the PDX cohort was tested
for the expression of human genes.Human-specific quantitative RT-PCR on CTCs in blood of
PDX mice
RNAs extracted from PDX blood samples were subjected
to three independent reverse-transcription reactions and
qPCR assays were performed on the pooled cDNAs. The
expression levels of the murine reference gene Actb
(mActb) and human reference genes OAZ1 and ACTB
were measured in each sample. Human cDNAs were
pre-amplified, and then subjected to nested-qPCR by
using human-specific primers (Additional file 2: Table S2).
No detection was obtained in control mice (no PDX) for
both human reference genes (no control mice had Ct
lower than 40), indicating that in our protocol the human
specific quantitative PCR did not lead to false positives.
The human references were amplified in five independent
qPCRs for each sample (replicated). Undetermined Ct
values were estimated by using the expectation–
maximization (EM) algorithm, as previously described
[30]. The blood from three PDX mice, HB-214-FOI(b),
T180R(c), HBCx-28(a), was negative for the humanFig. 1 Representative results from RT- PCR assays for human EPCAM detec
human gene were performed on pooled RNAs from human cell lines: ZR-7
cells (H), and on RNA from Sv/129 mouse PBMC (M). Each primer set was t
are indicated. Molecular weight marker: 100 bp DNA Ladder (NE Biolabs). b
from the naïve mouse used to generate the PDX models (naïve mouse) and o
controls respectively. Each assay was performed at least twice. The expected s
(NE Biolabs)reference genes, therefore had no detectable CTC and the
samples were thus excluded from further studies.
Expression of human CTC markers in blood from PDX mice
The expression levels of human EPCAM, KRT19, ACTB
and OAZ1 in the blood of PDX models were measured
using qPCR (Additional file 3: Table S3 and
Additional file 4: Table S4). The normalized expression
values for human genes were calculated relative to murine
Actb and shown in Fig. 2, sorted by the level of the human
OAZ1 reference gene (as approx. indicator of CTC
content). As expected for two ‘housekeeping’ genes, the
RNA levels of the two human reference genes (ACTB and
OAZ1) were significantly correlated (Spearman’s rho= 0.462,
p < 0.05). Ideally ACTB, OAZ1, or any other human
ʻhousekeepingʼ gene, would act as proxies for the assess-
ment of human CTC content in the PDX blood. We then
studied the expression of EPCAM and KRT19 epithelial
markers within the human CTC component. The normal-
ized expression values for human target genes were calcu-
lated relative to each human reference gene, using the ΔCt
method, obviously with no difference whether the human
genes were previously normalized on murine Actb. The
expected plots for the different hypotheses that EPCAM
levels were not (A), positively (B) or negatively (C) corre-
lated with the total human RNA content are shown in
Additional file 5: Figure S1, and describe the predictions
of EPCAM profiles relative to human OAZ1. Because the
plots report ΔCt values, the PDX samples with highertion in PDX blood. a RT-PCR assays confirming PCR specificity on
5-1, MCF-7, MDA-MB-231 breast cancer, and MDA-MB-435 melanoma
ested at least in two independent assays. The expected size fragments
The specificity of the nested-PCR assays was assessed on blood RNA
n the pooled human cell lines RNA (H), used as negative and positive
ize fragment is indicated. Molecular weight marker: 100 bp DNA Ladder
Fig. 2 Normalized expression levels of human genes. The expression levels of human ACTB and OAZ1 reference genes and EPCAM and KRT19
epithelial markers were normalized on murine reference gene Actb, for each PDX sample. Data were expressed as ΔCt values and graphed, sorted on
human OAZ1 content. Samples were analyzed in two independent assays for mActb; for human transcripts, qPCR was repeated in four (KRT19) or five
(ACTB, OAZ1, EPCAM) independent assays for each gene. In each run, each RNA was measured in duplicate
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are towards the left, and those with higher EPCAM in
CTC are towards the bottom. The null hypothesis was
that EPCAM, if present, was expressed by the CTCs at
constant cellular levels (RNA molecules per CTC cell) inFig. 3 Correlation of EPCAM expression and human RNA content in PDX c
references ACTB (in a) or OAZ1 (in b) and the human reference content re
expression levels were graphed as a scatterplot. Human reference gene Ct va
were normalized on human reference gene. The linear regression fit lines anddifferent PDXs; thus as human RNA content increases,
EPCAM levels should be correspondingly higher (result-
ing in relatively constant ΔCt(hEPCAM - hOAZ1) values);
this would correspond to the panel A in Additional file 5:
Figure S1 (flat line, no correlation). In Fig. 3 we report theohort. The correlation between EPCAM expression relative to human
lative to murine Actb was graphed. Each PDX blood sample gene
lues were normalized on the murine Actb gene. Human EPCAM Ct values
Spearman’s rho correlation coefficients are reported
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man reference RNAs. In the PDX cohort, the EPCAM
levels showed to be relatively constant, as the human con-
tent increased, indicative of a pattern similar to A in
Additional file 5: Figure S1 (stable reservoir of EPCAM+
cells). The same protocol was applied to KRT19, the most
common alternative marker for CTCs detection. As ob-
served for EPCAM, also KRT19 was expressed at similar
content in PDXs with diverse amounts of human refer-
ence RNAs (Fig. 4). No significant correlation was mea-
sured between the two epithelial markers (Spearman’s rho
= 0.219, relative to ACTB, and rho = 0.152, relative to
OAZ1; both p > 0.05) [31].
Discussion
Detection of circulating tumour cells in the blood of pa-
tients with cancer shows great potential as a ‘liquid bi-
opsy’, and multiple technologies have been developed for
CTC capture [4]. The limitations in current CTC detec-
tion are mainly due to reduced specificity and sensitivity
and should be carefully considered when interpreting
the literature [3]. The quest for technical developments
has slowed down the introduction of CTCs into clinical
diagnostics. However, new important insights into the
biology of CTCs have been reported [32], and tools for
combined enrichment, detection, and characterization of
CTCs are emerging.
Although the prognostic value of CTC has been demon-
strated [33–35], metastatic patients frequently present lit-
tle or undetectable CTCs when using epithelial markers
[12]. Otherwise, higher numbers of CTCs could be de-
tected using alternative methods, suggesting that aFig. 4 Correlation of KRT19 expression and human RNA content in PDX co
references ACTB (in a) or OAZ1 (in b) and the human reference content re
expression levels were graphed as a scatterplot. Human reference gene Ct va
were normalized on human reference gene. The linear regression fit lines andmixture of EPCAM+ and EPCAM- tumour cells circulate
in the blood [12, 36]. Therefore EpCAM-based CTC isola-
tion might suffer of limitations in the clinical settings
since its sensitivity is significantly dependent on EpCAM
expression [37]. Also, non-epithelial CTCs might exert a
more relevant function in tumorigenesis: indeed, mouse
models and in vitro experiments evidenced that EMT, to-
gether with stem-like properties in circulating cancer cells,
is associated with increased cellular migration and resist-
ance to therapy [16, 38]. Thus, the pre-selection for cells
that have retained significant expression of epithelial
markers represents an intrinsic challenge in studying CTCs
[27]. To overcome these limitations the isolation of CTCs
based on size has been described [8], reportedly leading to
higher CTC yields. A larger set of tumour-specific markers
would be then useful in establishing the identity of the het-
erogeneous CTCs enriched by filtration strategies, and to
rescue those that might escape.
To develop a method for the identification of undifferen-
tiated (or EPCAM-) CTCs, we used human specie-specific
qRT-PCR and blood from PDXs. PDX models represent an
ideal system for our study, allowing to exclusively profile
the human transcriptome in the CTCs, excluding a priori
the possible contamination of human mononuclear cells.
Species-specific primers were designed and validated in hu-
man cell lines and naïve mouse blood. Nested quantitative
human-specific qRT-PCR was established as a highly spe-
cific and sensitive method to detect and measure the ex-
pression of human CTC genes, with no detection of
murine genes. Human RNAs for reference genes and epi-
thelial markers were quantified in the blood of
patient-derived xenografts from breast cancer. The nullhort. The correlation between KRT19 expression relative to human
lative to murine Actb was graphed. Each PDX blood sample gene
lues were normalized on the murine Actb gene. Human KRT19 Ct values
Spearman’s rho correlation coefficients are reported
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would be expressed in CTCs at levels correlated to those of
the human housekeeping genes. These results were ob-
tained by using two different reference genes, OAZ1 and
ACTB (found to be correlated between them, as expected
for housekeeping genes), and also mirrored by another epi-
thelial marker, KRT19. Our findings confirmed that we
could reliably measure mRNA from rare CTCs, in the per-
ipheral blood, with the highest degree of sensitivity and spe-
cificity. Therefore our assay is able to determine the
presence of occult circulating tumour cells in the peripheral
blood and has the potential to identify novel CTC markers
using PDX mice. For the accurate measure of human CTC
content in PDX blood, genomic DNA would be used.
Tumour DNA content is more stable than RNA content,
thus in principle this measure could result in absolute CTC
counts. We decided to focus at first on human mRNA to
avoid any environmental contamination, which could
greatly affect the results of this extremely sensitive protocol.
The follow-up of this pilot study involves: i) identifica-
tion of novel CTC markers from PDX cohorts; ii) test of
these novel CTC markers in blood from human cancer
patients. Genes detected in the EPCAM-negative subset
of samples would lead to isolate CTC subpopulations
with intermediate or not well defined phenotype. Even-
tually a novel set of genes for CTCs capture would be
identified, allowing for capture of viable heterogeneous
CTCs in murine human cancer xenograft models. Tran-
scripts with no, or very low, expression in PBMC from
healthy donors could be used for CTC monitoring in
blood of tumour patients for clinical and research appli-
cations. At last, human genes expressed in blood of PDX
models, originating from circulating tumour cells, will
need to be validated in human blood specimens. The ap-
plication of our approach was originally addressed to the
detection and capture of human circulating tumour cells
deriving from solid tumours, first in PDX models and
then in patients. However, it can be applied in PDX
models also for human hematologic malignancies. Re-
cently, a model of human AML has been developed,
which efficiently recapitulated the pathological features,
including myeloid sarcoma, spleen enlargement, and in-
filtration of leukemic cells from bone marrow [39]. Since
our method is designed to discriminate the transcripts
from murine and human species in murine blood sam-
ples, circulating leukemic stem cells, which are believed
to influence engraftment potential in recipient mice and
are responsible for disease resistance or relapse in pa-
tients, could be easily examined.
Conclusions
It is in our plans to extend the number of human CTC
markers in the assay, the cohort of PDX mice, to incorp-
orate CTC counting by genomic DNA and to perform inparallel single-cell RNA sequencing. Using multiple tar-
gets for CTC capture and identification would increase
the comprehensiveness of CTC detection. Our work
shows the presence of heterogeneous molecular pheno-
types in CTCs from a PDX breast cancer cohort and
provides the basis for the detection of the diverse
spectrum of tumour cells that circulate in blood. Ultim-
ately, alternative methods for detection of CTCs from
human samples would be implemented. Extended mo-
lecular characterization of CTCs may provide further
insight into the biology of these cells and their link to
metastasis. Furthermore, molecular profiles of CTCs
could lead to novel non-invasive diagnostic tools, and
allow real-time monitoring of treatment responses. In
this context, we consider our protocol as a proof of con-
cept, with a great potential in opening up a new way to-
wards the identification of novel markers for CTC
capture.
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Additional file 5: Figure S1. Simulation and real data of human EPCAM
RNA detection in CTC from PDX blood. The expression values of EPCAM
in CTCs (relative to human reference OAZ1), as calculated for 3 different
trends are plotted: A, no variation of relative EPCAM levels among samples;
B, ~ 10% EPCAM levels increasing faster than human RNA content; C, ~ 10%
decreasing EPCAM faster than human RNA content. The PDX samples with
higher CTC content (more RNA from OAZ1 reference gene) are towards
the left and those with higher EPCAM in CTC are towards the bottom. The
measured EPCAM relative to human reference OAZ1 and the human OAZ1
CTC levels, normalized on murine Actb, are shown in panel D (from 5
independent qPCR experiments). The linear regression fit lines are reported.
(PDF 30 kb)
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